Sparks commentary - Basilea Pharmaceutica

Healthcare

Sparks - Basilea Pharmaceutica

More on this equity
misael-moreno-fN6K30xtiKE-unsplash-Basilea
Basilea Pharmaceutica (SIX: BSLN) reports its first ($5m) milestone payment for 2026
Published by Jyoti Prakash, CFA

Basilea Pharmaceutica has reported its first milestone payment for FY26, receiving $5m from Pfizer following Cresemba’s sales in Asia Pacific and China surpassing a predefined contractual threshold. The milestone compares favourably with the $2.5m payments received in March and June 2025, suggesting that a materially higher sales tier has now been achieved. We view this as evidence of continued commercial momentum, particularly in China, which management estimates to be c 20% of Cresemba’s total addressable opportunity.

Global in-market sales of Cresemba reached c $693m for the twelve months ended September 2025, implying c 27% y-o-y growth and reinforcing its position as the leading branded antifungal globally. On the back of the stronger-than-expected sales trajectory, we recently upgraded our peak sales estimate to c $900m in our latest research update.